96 Tests PN: B411090

Components:

45x Ab-conjugated beads (S4P - NHP Eotaxin Ab-bead). PN: B411090A. One vial containing 100 µL of anti-NHP Eotaxin conjugated to AimPlex Bead S4P1.

25x Biotin-detection Ab (NHP Eotaxin Biotin-dAb). PN: B411090B. One vial containing 100 µL of biotinylated anti-NHP Eotaxin.

Lyophilized Standard Mix-NHP Group 1 Panel B. PN: HG10011. One vial containing lyophilized recombinant Eotaxin, IL-1β, IL-1RA, IL-8, IL-12p70, IL-22, IP-10, MCP-1, MCP-3, and RANTES.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

Application: Optimal antibody pair and antigen standard for assaying human CCL/Eotaxin.  Can be multiplexed with other analytes in NHP Group 1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in NHP Group 1: Negligible

  • Sample volume: 15 µL/test

Description:

CCL11/Eotaxin-1 (Accession Q8MIT7) is a member of the CC chemokine subfamily. CC subfamily members can chemoattract and activate inflammatory lymphocytes, monocytes, eosinophils, and basophils. Eotaxin-1 specifically chemoattracts eosinophils from blood to sites of allergic inflammation.

It has been demonstrated, that exposing young mice to CCL11 or the blood plasma of older mice decreases the cognitive performance on behavioral tasks. CCL11 has also been shown to negatively affect hippocampal neurogenesis in human adults, thus suspected in having the ability to cross the blood-brain barrier. Eotaxin-1 entry into the central nervous system also has proven inhibitory effects on cognitive function and neurogenesis. Levels of Eotaxin-1 have been shown to increase in individuals with rheumatoid arthritis. Such pathways could be targeted in preventing bone destruction in diseases such as periodontitis, rheumatoid arthritis, or invading tumor processes.

References:

  1. Corrigan CJ. Eotaxin and asthma: some answers, more questions. Clin Exp Immunol. 1999;116(1):1–3. doi:10.1046/j.1365-2249.1999.00740.x

  2. Erickson MA, Morofuji Y, Owen JB, Banks WA. Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells. J Pharmacol Exp Ther. 2014;349(3):497–507. doi:10.1124/jpet.114.213074.

  3. Kindstedt E, Holm CK, Sulniute R, Martinez-Carrasco I, Lundmark R, Lundberg P. CCL11, a novel mediator of inflammatory bone resorption. Sci Rep. 2017;7(1):5334. Published 2017 Jul 13. doi:10.1038/s41598-017-05654-w.

  4. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin Induces a Rapid Release of Eosinophils and Their Progenitors From the Bone Marrow. Blood. 1998; 91: 2240-2248.